Very exciting times ahead. Key words are popping up again. FDA breakthrough device designation application, FDA approval process, clinical trials, commercialisation, industry partners are key coming up. enjoy the JOURNEY all. Very assuring for shareholders given their transparency and ongoing meeting of milestones. Don't expect anything sub par from this quality of managing who have experience within $1B+ MC companies.
- well on the way to achieving our vision of becoming a global leader in point of care imaging
- our technology has the potential to truly change the landscape of stroke care
- FDA engagement positive and look forward to the outcome of breakthrough device designation application
- equally excited on prospective industry partners - This has been mentioned many times in past announcements and I feel something is brewing with partners that when announced will be material. They are keeping it tight lipped for now.- JOURNEY to ultimately deploy our portable and accessible neuroimaging products GLOBALLY - No mucking around here, they are aiming for global take up.- ultimately deployment of our first commercial product
Ann: Appendix 4E & Annual Report 30 June 2021, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.99 |
Change
-0.040(1.97%) |
Mkt cap ! $169.9M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.01 | $1.99 | $7.404K | 3.701K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2953 | $1.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 799 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |